To look at the safety and effectiveness of stereotactic body radiation therapy (SBRT) in treating advanced or high-risk prostate cancer.
Pathologically (histologically or cytologically) proven diagnosis of adenocarcinoma of prostate within one year of study entry. Evaluation can happen outside of MD Anderson as long as histological confirmation takes place at MD Anderson.
cT1c-T3a by digital exam or imaging (AJCC 8th Ed.). No cT3b-4 by digital exam or imaging (AJCC 8th Ed.)
Gleason Grade Group 2-5 (Gleason 7, 8, 9, 10).
If Gleason Grade 2, must meet definition of unfavorable intermediate risk (at least one of the following: cT2b, and/or ≥ 50% biopsy cores positive, and/or PSA >10 ng/mL prior to starting androgen deprivation therapy (ADT).
Diagnosis of active scleroderma, lupus, or other rheumatologic disease which in the opinion of the treating radiation oncologist precludes safe RT.
Prior prostatectomy, cryosurgery, or HIFU for adenocarcinoma of the prostate
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation fields
Distant metastatic disease on conventional imaging, which by the discretion of the treating physician cannot be treated definitively.
Single group
Stereotactic Body Radiation Therapy
DeviceUndergo Radiation Therapy
Safety and adverse events (AEs)
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Click on the lead sponsor to view all of their trials.
